-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Ironwood Pharmaceuticals Inc annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate from 2021 to 2023.
- Ironwood Pharmaceuticals Inc Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2022 was $14.7M.
- Ironwood Pharmaceuticals Inc annual Deferred Income Tax Expense (Benefit) for 2023 was $72.6M, a 10.4% increase from 2022.
- Ironwood Pharmaceuticals Inc annual Deferred Income Tax Expense (Benefit) for 2022 was $65.7M.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)